|
注册号: Registration number: |
ChiCTR2400082315 |
|
最近更新日期: Date of Last Refreshed on: |
2025-03-27 17:44:38 |
|
注册时间: Date of Registration: |
2024-03-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于岛叶-下丘脑-rVLM的针刺调控原发性高血压中枢整合机制研究 |
|
Public title: |
Neuroimaging study on the central integration mechanism of acupuncture regulation in essential hypertension based on insula- hypothalamus-rVLM |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于岛叶-下丘脑-rVLM的针刺调控原发性高血压中枢整合机制研究 |
|
Scientific title: |
Neuroimaging study on the central integration mechanism of acupuncture regulation in essential hypertension based on insula- hypothalamus-rVLM |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
魏晓雅 |
研究负责人: |
刘存志 |
|
Applicant: |
Xiaoya Wei |
Study leader: |
Cunzhi Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 188 1136 6360 |
研究负责人电话:
Study leader's |
+86 10 5391 2201 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
weixy0520@163.com |
研究负责人电子邮件: Study leader's E-mail: |
lcz_tg@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区北三环东路11号 |
研究负责人通讯地址: |
北京市朝阳区北三环东路11号 |
|
Applicant address: |
11 North Third Ring Road East, Chaoyang District, Beijing |
Study leader's address: |
11 North Third Ring Road East, Chaoyang District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京中医药大学针灸推拿学院 |
||
|
Applicant's institution: |
School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine |
||
|
研究负责人所在单位: |
北京中医药大学针灸推拿学院 |
||
|
Affiliation of the Leader: |
School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024BZYLL0107 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京中医药大学医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Beijing University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-14 00:00:00 | ||
|
伦理委员会联系人: |
李梅 |
||
|
Contact Name of the ethic committee: |
Mei Li |
||
|
伦理委员会联系地址: |
北京市朝阳区北三环东路11号 |
||
|
Contact Address of the ethic committee: |
11 North Third Ring Road East, Chaoyang District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 5391 1431 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京中医药大学针灸推拿学院 |
||||||||||||||||||||||
|
Primary sponsor: |
School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区北三环东路11号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
11 North Third Ring Road East, Chaoyang District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金重点项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
State Key Program of National Natural Science Foundation of China |
||||||||||||||||||||||
|
研究疾病: |
高血压 |
||||||||||||||||||||||
|
Target disease: |
hypertension |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价针刺治疗原发性高血压的疗效,并探索针刺作用的神经机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
Evaluate the efficacy of acupuncture on essential hypertension and explore the neural mechanism of acupuncture treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.肾实质性疾病、肾动脉狭窄及其他血管病、阻塞性睡眠呼吸暂停综 合征、原发性醛固酮增多症等影响血压的疾病; 2.过去 1 个月使用影响血压的其他药物(除外降压药):如激素类药 物、中枢神经类药物、非甾体类抗炎药物等; 3.未受控制的糖尿病(糖化血红蛋白≥6.5%); 4.怀疑或确有酒精、药物滥用病史; 5.备孕、育龄期妇女未避孕者、妊娠期及哺乳期妇女; 6.体内携带心脏起搏器、除颤器、血管夹、植入性电或磁装置、机械心脏瓣膜、人工耳蜗等功能磁共振(fMRI )禁忌物及幽闭恐惧症者;脸部或者眼睛内有金属碎片,从事金属相关工作;MRI 扫描 中发现有明确器质性病变或严重头颅解剖结构不对称者;其他原因不能接受 fMRI 扫描者; 7. 近 3 月内因高血压病接受针灸治疗; 8 近 1 个月参加其他临床试验的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Other diseases that can affect the blood pressure, including but not limited to diseases of renal parenchyma, renal artery stenosis, obstructive sleep apnoea syndrome, and primary hyperaldosteronism; 2. Receiving medicines that affect blood pressure except antihypertensive drugs in last month, including but not limited to glucocorticoids and central nervous system inhibitors; 3. Uncontrolled diabetes (HbA1c≥6.5%); 4. Drug or alcohol abuse; 5. Pregnant women, pregnant and lactating women; 6. Carry fMRI contraindications such as pacemakers, defibrillators, vascular clips, implanted electrical or magnetic devices, mechanical heart valves, cochlear implants, and claustrophobia; engaged in metal related work with metal fragments in the face or eyes; severe skull anatomical asymmetry or definite lesions were found in MRI scanning; cannot accept fMRI scans for other reasons; 7. History of receiving acupuncture treatment for hypertension within 3 months; 8. Participated in other clinical trials in the past 1 months. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-04-15 00:00:00至 To 2026-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-09-21 00:00:00 至 To 2026-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用区组随机,随机序列由一位专业的统计学家用Stata软件产生 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The blocked randomization sequence was prepared by a professional statistician with the Stata software |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本试验对受试者、数据收集/录入者和统计人员设置盲法 |
|
Blinding: |
Patients, outcome assessor and statistician will be blinded to the assignments. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月内,通过中国临床试验注册中心的ResMan平台进行原始数据的共享(http://www.medresman.org/login.aspx) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Within 6 months after the trial complete, we will share IPD based on the ResMan platform (http://www.medresman.org/login.aspx) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
通过纸质CRF表格记录元数据,再由两人交叉核对将数据转录到epidata建立的数据库。数据管理由专人负责。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The records of metadata are recorded through a CRF form, and then cross-checked and transcribed to an electronic database file based on Epidata software. All the data management is handled by an independent person. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |